Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Delayed NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
1,497 INR +2.30% Intraday chart for Cipla Limited +3.33% +20.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cipla Gets Regulatory Nod to Merge US-Based Subsidiaries MT
Cipla to Distribute Sanofi's CNS Product Line in India MT
Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024 CI
Losses Led by IT Drag Indian Equities on Tuesday MT
Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024 CI
Indian Equities Close with Marginal Gains on Tuesday as IT Stocks See Drop MT
Cipla Arm Completes Sale of Entire Stake in Wellthy MT
India pharma companies develop versions of Wegovy to get in on weight-loss windfall RE
Indian Equities Close Higher Midweek, Led by Banking, IT Stocks MT
Indian drugmaker Lupin beats quarterly profit estimates on strong demand RE
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand RE
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales RE
Cipla Eyes Acquisitions and Inorganic Partnerships in the US, European markets CI
India's Jubilant Pharmova posts quarterly profit RE
India's Torrent Pharma posts higher Q3 profit on strong domestic demand RE
Loss in Bank Stocks Drags Indian Equities to End Lower on Thursday MT
Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses RE
Nomura Downgrades Cipla to Neutral From Buy, Price Target to INR1,427 From INR1,353 MT
Indian Equities End Strongly on Monday Ahead of Interim Budget, US Rate Decision MT
Jefferies Adjusts Cipla’s Price Target to INR1,250 From INR1,210, Keeps at Hold MT
Selling in IT, Banking Stocks Drag Indian Equities on Thursday MT
Transcript : Cipla Limited, Q3 2024 Earnings Call, Jan 25, 2024
Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson CI
Cipla Seeks Inorganic Growth CI
Cipla Forms New Mexican Subsidiary MT
Chart Cipla Limited
More charts
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,497 INR
Average target price
1,445 INR
Spread / Average Target
-3.46%
Consensus
  1. Stock
  2. Equities
  3. Stock Cipla Limited - NSE India S.E.
  4. News Cipla Limited
  5. Cipla : Partners with Premier Medical Corporation for COVID-19 Rapid Tests